Table 2.
Activity of the synthesized peptides against SARS-CoV-2 in Vero cells.
| compound | Antiviral activity (EC50, μM)a |
Cytotoxicity (μM) |
|||
|---|---|---|---|---|---|
| UC-1074 | RG2674 | NVDBB-2220 | Cell morphology (MCC)b | Cell growth (CC50)c | |
| 4 | 66.1 ± 4.1 | >100 ± 0 | 40.3 ± 6.2 | ≥100 | >100 ± 0 |
| 57 | 50.2 ± 7.8 | 84.9 ± 26.2 | 43.3 ± 4.8 | ≥100 | >100 ± 0 |
| 58 | 5.0 ± 2.2 | 39.9 ± 12.1 | 5.2 ± 4.5 | ≥100 | >100 ± 0 |
a
Effective concentration required to reduce virus induced cytopathic effect by 50%. Virus input was 100 CCID50.
b
Minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology.
c
Cytotoxic concentration required to reduce cell growth by 50%.